Does 700 mg of CBD Cause Sedation or Reduce Cortical Excitability? A 25-Man Crossover Trial

Answer: In a randomized, double-blind, three-period crossover experiment, single oral doses of 30 mg and 700 mg cannabidiol (CBD) produced measurable CBD concentrations in separated blood plasma but no statistically significant differences from placebo on the prespecified TMS–EMG measures, eye-movement tests, postural sway, adaptive tracking, memory tests, or subjective sedation measures reported in the main outcome table. Several localized TMS–EEG response clusters did differ significantly, including after 700 mg CBD. Their direction and biological meaning were uncertain. These results do not establish that CBD can never impair an individual, that it lacks clinical antiseizure efficacy, or that a plasma CBD number diagnoses fitness to drive.

The original primary investigation was conducted by Gorbenko and colleagues, published in Clinical Pharmacology & Therapeutics (volume 119, issue 1, January 2026; accepted August 2025). Its full scientific record is identified by DOI 10.1002/cpt.70038. For forensic review, its value lies in connecting directly assayed plasma exposure with several distinct laboratory measures of brain responsiveness and performance without pretending that any one is an individualized intoxication test.

What, exactly, was the forensic question this experiment could answer?

A frequent litigation shortcut is to treat a cannabinoid concentration, a dose listed on a medication label, and observed functional impairment as interchangeable. They are not. This study offers a relatively controlled comparison of pharmacokinetic exposure and test-battery outcomes after oral CBD alone. It helps assess a narrow proposition: whether these two single doses produced group-level changes in the tests the investigators used during the observation interval.

It was not a roadside validation, crash-reconstruction experiment, workplace fitness evaluation, or clinical epilepsy efficacy trial. The investigators did not conduct a prospective blinded classification of “impaired” versus “unimpaired” drivers, did not validate a plasma threshold for impairment, and did not quantify parent THC in participants as an outcome. A numerical null on one measure cannot be converted into proof that an individual performed safely on every unmeasured activity.

Who participated, and why do the denominators matter?

Forty-one men were screened. Twenty-five healthy men were randomized and received at least one dose. One participant discontinued after a cannula-related superficial thrombophlebitis event; the investigator considered it unrelated to study medication. Twenty-four finished the complete crossover protocol. The source reports pharmacokinetic parameters for 25 observations in the 30-mg period and 24 in the 700-mg period. These are not 49 different people: dose-period measurements came from a largely shared cohort.

The age-eligibility range was 18–55 years. Women were intentionally excluded because the authors wanted to limit potential menstrual-cycle effects on cortical excitability. This design choice matters whenever a witness tries to apply the findings to women, older adults, people with substantial illnesses, patients taking sedatives, or individuals receiving repeated chronic cannabinoid therapy. The study does not directly cover those groups.

How did the three-period design isolate CBD effects?

Each volunteer was assigned three visits separated by two-week washout periods. The blinded conditions were a 30-mg oral CBD dose, a 700-mg oral CBD dose, and matched placebo. The CBD formulation was an almond-oil solution; placebo included the corresponding vehicle and flavoring. The researchers used a balanced randomized sequence rather than comparing two unrelated groups.

The low dose was intended to resemble an over-the-counter exposure, while the larger single dose approximated one therapeutic-size administration in the study’s rationale. Neither should be generalized to every retail preparation, route of administration, or long-term treatment schedule. The formulation, meal and fasting restrictions, and sampling clock can all influence the resulting exposure.

Repeated within-person measurements strengthen the dose comparison because stable participant characteristics are partly controlled. They do not remove all uncertainty. Practice, incomplete participation, assay measurement error, temporal sensitivity of the tests, and the fact that all participants were healthy men continue to matter.

What was chemically measured, and what was only a proxy?

Direct chemical assay: Venous blood was drawn before dosing and at two, three, four, five, and six hours. The laboratory measured CBD in plasma separated from blood, using a validated bioanalytical method with a stated lower limit of quantification of 0.75 ng/mL. The published paper gives plasma concentration–time profiles, peak concentration (C_max) and area under the concentration–time curve to the last measurable observation (AUC_last).

Not a direct CBD blood assay: Transcranial magnetic stimulation with electromyography (TMS–EMG) evaluates evoked muscle responses and motor-cortex excitability. Stimulation with electroencephalography (TMS–EEG) records electrical response potentials. Eye tracking, body sway, reaction-time tasks, memory tests and questionnaire scores are distinct functional or subjective outcomes. None is a concentration of CBD, THC, or another drug in venous whole blood.

The plasma values here are also not statutory whole-blood THC concentrations, urine THC-COOH results, a breath-alcohol reading, or a tested drug-screen cross-reactivity threshold. Forensic conclusions must retain the actual specimen type and measured analyte.

What plasma exposure followed the 30-mg and 700-mg doses?

Both doses led to measurable CBD exposure. The mean plasma peak after 30 mg was 8.8 ng/mL, compared with 395 ng/mL after 700 mg. Mean AUC_last was 20.3 versus 931 h·ng/mL. Median time to the peak was three hours for both doses, with reported ranges of two to four hours. The high-dose measurements varied substantially between participants; its peak values ranged from 160 to 866 ng/mL.

These are exposure statistics, not impairment scores. AUC_last has units of concentration multiplied by time. It cannot be inserted into a whole-blood-per-se statute as though it were the concentration in an individual sample. Nor is the highest group mean a patient-specific cutoff.

Was the dose–plasma concentration relation linear?

No simple proportional relationship emerged across these two single doses. Raising the administered dose from 30 mg to 700 mg multiplies the dose by about 23.3, whereas the study’s mean peak plasma CBD and mean AUC_last increased by about 45-fold. The authors explicitly described exposure as increasing more than dose-proportionally. Those are calculations from the study’s two administered regimens, not proof of a universal CBD conversion equation.

The investigators discussed possible formulation-related absorption effects and other mechanistic explanations, but did not establish a direct cause of the nonlinearity. There were only two active dose levels, a particular oil preparation, a limited sampling interval, and healthy male volunteers. The finding cannot reliably back-calculate how much an unknown person consumed from one later plasma measurement.

Did conventional TMS–EMG identify decreased excitability?

No statistically significant treatment effect was reported for resting motor threshold, single-pulse motor-evoked potential amplitude, or the paired-pulse parameters assessing short-interval intracortical inhibition, intracortical facilitation, and long-interval intracortical inhibition. For example, the estimated mean motor-evoked amplitude difference from placebo was +1.9% for 30 mg (p = .86) and −2.9% for 700 mg (p = .78). Both estimates had wide confidence intervals spanning meaningful increases and decreases.

Resting motor threshold also failed to meet conventional statistical significance: the high-dose comparison was −1.2 percentage points of maximum stimulator output (p = .08), with a confidence interval from −2.6 to +0.1. Describing that as a proven decrease would misstate the original test. Conversely, a nonsignificant result cannot exclude every physiologically relevant change smaller than the study was powered to detect.

The sample-size calculation was geared toward detecting a specified effect on motor-evoked potentials. It was not a separate high-powered equivalence or noninferiority trial for every measure in the battery. A null finding is appropriately phrased as no significant difference detected under these conditions, not the two conditions are medically identical.

Were there any significant brain-response findings?

Yes. A careful review must report them rather than presenting the entire experiment as universally negative. With single-pulse TMS–EEG, the 30-mg condition showed a localized difference in an early N15 component at three hours (p = .02). At 700 mg, paired-pulse TMS–EEG showed localized N45 and P60 differences at three hours (p = .01 and .03), and P30 and N45 differences at five hours (both p = .04).

Those were spatial–temporal electrode clusters identified using permutation-based analyses. A cluster’s statistical significance does not determine whether neural inhibition increased, whether clinical seizure protection occurred, or whether reaction time deteriorated. The source authors considered the physiological interpretation of paired-pulse TMS–EEG uncertain. The small early low-dose finding was not replicated at the larger dose; its clinical relevance is therefore especially unclear.

Multiple physiological outcomes, electrode clusters and time points were investigated. The paper did not use a general multiple-comparison correction for the main exploratory mixed-model outcomes, although the EEG-cluster procedure itself used permutation inference. That analytic distinction belongs in any forensic appraisal of apparently exceptional significant findings.

Did eye movements, postural sway, and vigilance show sedation?

Not on the reported group comparisons. The test battery included saccadic peak velocity, smooth pursuit, adaptive tracking, body sway, subjective alertness, calmness and mood, and measures of feeling high or altered perception. Both CBD doses generally produced estimates close to placebo relative to the variation in those outcomes, with no conventional statistically significant active-versus-placebo effect in the main results table.

At 700 mg, for example, the reported adaptive-tracking difference was −0.59 percentage points (95% confidence interval −1.77 to +0.59; p = .31), and the saccadic peak-velocity estimate was −1.74 degrees/second (p = .69). Body-sway comparisons yielded p = .58 for both doses. The observed data do not support claiming a reliable decrease in tracking performance or a reliable increase in instability in this particular experiment.

Nevertheless, neither an eye-movement null nor a balance null should be reclassified as proof that every task involving vision, driving, equipment operation or multitasking remained unaffected. The trial evaluated a defined battery at selected times in a small, medically screened sample.

What happened to working memory and verbal learning?

Computerized n-back testing and a visual-verbal learning test addressed cognitive performance more directly than the EEG measurements. The 700-mg versus placebo reaction-time difference on the 1-back test was +15.95 ms (p = .14), and the 2-back difference was −12.55 ms (p = .46). Neither met the study’s significance threshold. The ratio correct on 2-back differed by +0.019 (p = .40). Verbal delayed recall at the high dose differed by −0.6 items (p = .37).

Such estimates are best conveyed together with their uncertainty and task specificity. In particular, “no significant change in n-back accuracy” is not the same proposition as “the participant can perform complex freeway driving without any CBD-related decrement.” A simulator, on-road evaluation, divided-attention driving protocol, or validated individualized impairment diagnostic assessment was not performed.

The table combines measurements that answer different questions. A significant EEG-cluster finding is not an impaired-driver detection rate, just as an insignificant reaction-time difference is not a drug-free assay result.

Why is a nonsignificant result not proof of no effect?

Statistical significance depends on sample size, noise, chosen endpoint, timing and the model. A test can fail to reject a null even when its confidence interval leaves clinically relevant effects plausible. This trial enrolled 25 men and had 24 protocol completers; several estimates retained broad intervals. The authors did not conduct a formal demonstration that both doses were equivalent to placebo on every task, nor establish minimum clinically important differences for every outcome.

There is also a difference between group averages and person-level responses. An apparently small average can arise when individuals respond differently. A cross-sectional forensic opinion about one driver, claimant, patient or employee would require contemporaneous facts and appropriate individualized testing rather than automatic extrapolation from this trial.

Does this experiment prove CBD works—or does not work—for epilepsy?

No. The participants did not have epilepsy and seizure frequency was not an outcome. Cortical-excitability signatures are mechanistic surrogate measures, and transfer to clinical seizure syndromes is imperfect. The authors argued that the weak conventional excitability signature was consistent with a hypothesis that coadministered antiseizure medication, particularly clobazam, explains a portion of CBD’s clinical effects. That is a scientific interpretation, not proof in this experiment that CBD cannot work independently.

No clobazam-treated comparison arm was randomized here, and no patient seizure endpoints were analyzed. The paper itself discusses clinical data that complicate simple dismissal of independent CBD benefit. For a treatment-causation claim, the relevant question is the particular diagnosed syndrome, co-medications, dosing schedule, clinical outcome, and evidence from patient trials—not whether a healthy volunteer’s TMS–EMG value crossed p < .05.

What does the study imply for a claimed CBD-related driving impairment?

The study provides limited negative evidence against consistent, readily detectable group-level sedation or memory impairment after single 30-mg or 700-mg doses in its screened male cohort. It provides neither a scientifically validated “safe driving” concentration nor a universal rule that high plasma CBD excludes functional effects. It did not measure road behavior, crashes, emergency evasive responses, combined alcohol/CBD effects, prescription-drug interactions in patients, or chronic dosing adaptations.

A case reviewer should distinguish the following evidentiary chain: verified identity and timing of the product; administered dose and route; direct chemical assay with specimen matrix and method; any co-exposure; an observed, appropriately standardized behavioral measure; and the legally relevant question. Breaking the chain by substituting CBD plasma AUC for driving ability, or substituting a subjective feeling for chemical confirmation, produces an inference the original experiment never validated.

What are the most important limitations to report in testimony?

The cohort comprised only healthy adult men; one participant did not complete all periods. Exposure followed one almond-oil formulation in single doses under controlled meal conditions. Testing occurred within hours, not after weeks of chronic treatment. Analytic sensitivity was finite, and concentrations below quantification were treated as missing in the pharmacokinetic computations. Some endpoints were exploratory and numerous tests were performed. TMS–EEG responses were not straightforwardly interpretable as clinically beneficial or harmful. The researchers reported no actual clinical seizures or real-world driving outcomes.

These limitations do not make the data worthless. They define the boundary of a reliable inference. The strongest accurate formulation is that the trial found substantial directly measured CBD plasma exposure, mostly nonsignificant conventional physiological and neurobehavioral comparisons, and several significant EEG response clusters of uncertain clinical meaning.

Frequently asked questions about CBD, cortical excitability and impairment

1. Did the study show that 700 mg CBD made volunteers sleepy?

No significant placebo-adjusted sedative effect was detected on the particular eye-movement, tracking, sway and subjective-state measures used. That is a group-level null result, not proof that all individuals, patients or combinations of medications are free of sedation risk.

2. Was CBD actually measured in blood?

Yes, CBD was measured in separated plasma from venous draws. Whole-blood parent THC and legal whole-blood impairment thresholds were not outcomes of this trial. Plasma CBD exposure must retain its proper units and matrix label.

3. Why were some EEG results significant when the conclusion emphasized no reduction in excitability?

Specific spatial and temporal TMS–EEG response clusters differed from placebo. The authors could not reliably translate those electrical changes into a net decrease in clinical cortical excitability, anticonvulsant efficacy, or observable behavioral impairment.

4. Can I compare a 395 ng/mL plasma CBD peak to a statutory THC threshold?

No. CBD is a different analyte from THC, and separated plasma differs from venous whole blood. The number is the high-dose group’s mean observed plasma CBD peak, not a legal THC concentration and not an individualized threshold.

5. Did higher CBD exposure mean greater memory impairment?

Not as a demonstrated result of this experiment. The 700-mg period had substantially greater plasma exposure, but the reported n-back and verbal-learning comparisons did not show statistically significant decrements from placebo. The study did not establish an individual exposure–impairment calibration curve.

6. Does the absence of a significant TMS–EMG effect prove CBD has no antiseizure activity?

No. Healthy participants had no seizure outcomes, and TMS–EMG is a physiological proxy. Clinical seizure reduction in defined patient groups requires evidence from appropriately designed patient studies, including careful consideration of co-medications.

7. Can this trial establish that CBD did or did not cause a particular collision?

No. It included neither an actual collision nor a prospective driving-performance validation. Causation in an individual event requires case-specific toxicological, temporal, medical and behavioral evidence; this trial cannot supply missing case facts.

Source and scope of this interpretation

This article critically examines the original randomized crossover experiment by Gorbenko and colleagues, Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial, Clinical Pharmacology & Therapeutics 119:147–157, January 2026, DOI 10.1002/cpt.70038. The findings described above are direct observations or estimates in that article. They are not a substitute for independent confirmatory toxicology, individualized clinical evaluation, or proof of legal impairment or specific event causation.